Company · Québec, Quebec, Canada
NB Pharma Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 109
- 109 authorized now
- Natural health products
- 6
- 6 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 46
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| NB-AMLODIPINE | 02556707 | Marketed | |
| NB-AMLODIPINE | 02556715 | Marketed | |
| NB-AMLODIPINE | 02556723 | Marketed | |
| NB-APIXABAN | 02553635 | Marketed | |
| NB-APIXABAN | 02553643 | Marketed | |
| NB-BISOPROLOL TABLETS | 02558556 | Marketed | |
| NB-BISOPROLOL TABLETS | 02558564 | Marketed | |
| NB-CIPROFLOXACIN | 02567636 | Marketed | |
| NB-CIPROFLOXACIN | 02567644 | Marketed | |
| NB-CITALOPRAM | 02555999 | Marketed | |
| NB-CITALOPRAM | 02556006 | Marketed | |
| NB-DONEPEZIL | 02568063 | Marketed | |
| NB-DONEPEZIL | 02568071 | Marketed | |
| NB-IRBESARTAN | 02560070 | Marketed | |
| NB-IRBESARTAN | 02560089 | Marketed | |
| NB-IRBESARTAN | 02560097 | Marketed | |
| NB-LANSOPRAZOLE | 02561239 | Marketed | |
| NB-LANSOPRAZOLE | 02561247 | Marketed | |
| NB-MONTELUKAST | 02565579 | Marketed | |
| NB-PANTOPRAZOLE | 02557304 | Marketed | |
| NB-PERINDOPRIL | 02555697 | Marketed | |
| NB-PERINDOPRIL | 02555700 | Marketed | |
| NB-PERINDOPRIL | 02555719 | Marketed | |
| NB-PREGABALIN | 02554836 | Marketed | |
| NB-PREGABALIN | 02554844 | Marketed | |
| NB-PREGABALIN | 02554852 | Marketed | |
| NB-PREGABALIN | 02554860 | Marketed | |
| NB-PREGABALIN | 02554887 | Marketed | |
| NB-QUETIAPINE XR | 02556820 | Marketed | |
| NB-QUETIAPINE XR | 02556839 | Marketed | |
| NB-QUETIAPINE XR | 02556847 | Marketed | |
| NB-QUETIAPINE XR | 02556855 | Marketed | |
| NB-QUETIAPINE XR | 02556863 | Marketed | |
| NB-RISEDRONATE | 02561859 | Marketed | |
| NB-RIVAROXABAN | 02555107 | Marketed | |
| NB-RIVAROXABAN | 02555115 | Marketed | |
| NB-RIVAROXABAN | 02555123 | Marketed | |
| NB-RIVAROXABAN | 02555131 | Marketed | |
| NB-ROSUVASTATIN | 02555492 | Marketed | |
| NB-ROSUVASTATIN | 02555506 | Marketed | |
| NB-ROSUVASTATIN | 02555514 | Marketed | |
| NB-ROSUVASTATIN | 02555522 | Marketed | |
| NB-SERTRALINE | 02556235 | Marketed | |
| NB-SERTRALINE | 02556243 | Marketed | |
| NB-SERTRALINE | 02556251 | Marketed | |
| NB-VALACYCLOVIR | 02558130 | Marketed | |
| NB-ALENDRONATE-FC | 02564335 | Approved | |
| NB-APIXABAN TABLET | 02569183 | Approved | |
| NB-APIXABAN TABLET | 02569191 | Approved | |
| NB-ARIPIPRAZOLE | 02557932 | Approved | |
| NB-ARIPIPRAZOLE | 02557940 | Approved | |
| NB-ARIPIPRAZOLE | 02557959 | Approved | |
| NB-ARIPIPRAZOLE | 02557967 | Approved | |
| NB-ARIPIPRAZOLE | 02557975 | Approved | |
| NB-ARIPIPRAZOLE | 02557983 | Approved | |
| NB-ATORVASTATIN | 02555581 | Approved | |
| NB-ATORVASTATIN | 02555603 | Approved | |
| NB-ATORVASTATIN | 02555611 | Approved | |
| NB-ATORVASTATIN | 02555638 | Approved | |
| NB-BISOPROLOL TABLETS | 02558521 | Approved | |
| NB-BISOPROLOL TABLETS | 02558548 | Approved | |
| NB-CANDESARTAN | 02566052 | Approved | |
| NB-CANDESARTAN | 02566079 | Approved | |
| NB-CANDESARTAN | 02566095 | Approved | |
| NB-CANDESARTAN | 02566109 | Approved | |
| NB-CANDESARTAN HCT | 02568632 | Approved | |
| NB-CANDESARTAN HCT | 02568640 | Approved | |
| NB-CANDESARTAN HCT | 02568659 | Approved | |
| NB-CIPROFLOXACIN | 02567652 | Approved | |
| NB-CITALOPRAM | 02556014 | Approved | |
| NB-DAPAGLIFLOZIN | 02560933 | Approved | |
| NB-DAPAGLIFLOZIN | 02560941 | Approved | |
| NB-DULOXETINE | 02561263 | Approved | |
| NB-DULOXETINE | 02561271 | Approved | |
| NB-EZETIMIBE | 02571218 | Approved | |
| NB-IRBESARTAN HCT | 02570211 | Approved | |
| NB-IRBESARTAN HCT | 02570238 | Approved | |
| NB-IRBESARTAN HCT | 02570246 | Approved | |
| NB-LEVETIRACETAM | 02569426 | Approved | |
| NB-LEVETIRACETAM | 02569434 | Approved | |
| NB-LEVETIRACETAM | 02569442 | Approved | |
| NB-LEVETIRACETAM | 02569450 | Approved | |
| NB-OLANZAPINE | 02570688 | Approved | |
| NB-OLANZAPINE | 02570696 | Approved | |
| NB-OLANZAPINE | 02570718 | Approved | |
| NB-OLANZAPINE | 02570726 | Approved | |
| NB-OLANZAPINE | 02570734 | Approved | |
| NB-PANTOPRAZOLE | 02557312 | Approved | |
| NB-PRAMIPEXOLE | 02566184 | Approved | |
| NB-PRAMIPEXOLE | 02566192 | Approved | |
| NB-PRAMIPEXOLE | 02566206 | Approved | |
| NB-PRAMIPEXOLE | 02566214 | Approved | |
| NB-PREGABALIN | 02554879 | Approved | |
| NB-RISPERIDONE | 02555352 | Approved | |
| NB-RISPERIDONE | 02555360 | Approved | |
| NB-RISPERIDONE | 02555379 | Approved | |
| NB-RISPERIDONE | 02555387 | Approved | |
| NB-RISPERIDONE | 02555395 | Approved | |
| NB-RISPERIDONE | 02555409 | Approved | |
| NB-RIZATRIPTAN RDT | 02560402 | Approved | |
| NB-RIZATRIPTAN RDT | 02560410 | Approved | |
| NB-SITAGLIPTIN | 02558807 | Approved | |
| NB-SITAGLIPTIN | 02558823 | Approved | |
| NB-SITAGLIPTIN | 02558831 | Approved | |
| NB-SITAGLIPTIN-METFORMIN | 02559633 | Approved | |
| NB-SITAGLIPTIN-METFORMIN | 02559641 | Approved | |
| NB-SITAGLIPTIN-METFORMIN | 02559668 | Approved | |
| NB-TAMSULOSIN CR | 02568721 | Approved | |
| NB-VALACYCLOVIR | 02558149 | Approved |
Natural health products
Active licences first, newest first.
| Name | NPN | Status | Licensed |
|---|---|---|---|
| NB-D400 | 80148339 | Active | |
| NB-D1000 | 80148338 | Active | |
| NB-Sennosides | 80143194 | Active | |
| NB-Calcium 500 | 80142485 | Active | |
| NB-Cal500 D1000 | 80142336 | Active | |
| NB-Cal500 D400 | 80142312 | Active |
Notices of Compliance
Newest first.
- NB-DULOXETINEOctober 5, 2026 · NOC 38403 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-CIPROFLOXACINSeptember 24, 2026 · NOC 38349 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-EZETIMIBEAugust 31, 2026 · NOC 38206 · Abbreviated New Drug Submission (ANDS)
- NB-OLANZAPINEAugust 7, 2026 · NOC 38072 · Abbreviated New Drug Submission (ANDS)
- NB-RIVAROXABANJuly 27, 2026 · NOC 37997 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-IRBESARTAN HCTJuly 22, 2026 · NOC 37966 · Abbreviated New Drug Submission (ANDS)
- NB-CITALOPRAMJuly 15, 2026 · NOC 37913 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-DULOXETINEJuly 13, 2026 · NOC 37896 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-LEVETIRACETAMJune 23, 2026 · NOC 37757 · Abbreviated New Drug Submission (ANDS)
- NB-APIXABAN TABLETJune 19, 2026 · NOC 37739 · Abbreviated New Drug Submission (ANDS)
- NB-TAMSULOSIN CRMay 29, 2026 · NOC 37634 · Abbreviated New Drug Submission (ANDS)
- NB-CANDESARTAN HCTMay 26, 2026 · NOC 37618 · Abbreviated New Drug Submission (ANDS)
- NB-DONEPEZILMay 4, 2026 · NOC 37472 · Abbreviated New Drug Submission (ANDS)
- NB-IRBESARTANApril 21, 2026 · NOC 37379 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-CIPROFLOXACINApril 9, 2026 · NOC 37398 · Abbreviated New Drug Submission (ANDS)
- NB-ATORVASTATINApril 8, 2026 · NOC 37283 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-MONTELUKASTMarch 3, 2026 · NOC 37028 · Abbreviated New Drug Submission (ANDS)
- NB-PRAMIPEXOLEFebruary 25, 2026 · NOC 36973 · Abbreviated New Drug Submission (ANDS)
- NB-CANDESARTANFebruary 24, 2026 · NOC 36965 · Abbreviated New Drug Submission (ANDS)
- NB-ALENDRONATE-FCJanuary 2, 2026 · NOC 36666 · Abbreviated New Drug Submission (ANDS)
- NB-ARIPIPRAZOLEDecember 29, 2025 · NOC 36645 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-APIXABANNovember 3, 2025 · NOC 36306 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-RISEDRONATEOctober 7, 2025 · NOC 36122 · Abbreviated New Drug Submission (ANDS)
- NB-DULOXETINESeptember 22, 2025 · NOC 36042 · Abbreviated New Drug Submission (ANDS)
- NB-LANSOPRAZOLESeptember 18, 2025 · NOC 36022 · Abbreviated New Drug Submission (ANDS)
- NB-ROSUVASTATINSeptember 12, 2025 · NOC 35992 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NB-DAPAGLIFLOZINSeptember 3, 2025 · NOC 35952 · Abbreviated New Drug Submission (ANDS)
- NB-RIZATRIPTAN RDTAugust 15, 2025 · NOC 35847 · Abbreviated New Drug Submission (ANDS)
- NB-IRBESARTANAugust 1, 2025 · NOC 35793 · Abbreviated New Drug Submission (ANDS)
- NB-SITAGLIPTIN-METFORMINJuly 21, 2025 · NOC 35698 · Abbreviated New Drug Submission (ANDS)
- NB-SITAGLIPTINJune 25, 2025 · NOC 35563 · Abbreviated New Drug Submission (ANDS)
- NB-BISOPROLOL TABLETSJune 19, 2025 · NOC 35546 · New Drug Submission (NDS)
- NB-VALACYCLOVIRJune 3, 2025 · NOC 35465 · Abbreviated New Drug Submission (ANDS)
- NB-ARIPIPRAZOLEMay 27, 2025 · NOC 35423 · Abbreviated New Drug Submission (ANDS)
- NB-PANTOPRAZOLEApril 29, 2025 · NOC 35265 · Abbreviated New Drug Submission (ANDS)
- NB-QUETIAPINE XRApril 10, 2025 · NOC 35156 · Abbreviated New Drug Submission (ANDS)
- NB-AMLODIPINEApril 2, 2025 · NOC 35114 · Abbreviated New Drug Submission (ANDS)
- NB-SERTRALINEMarch 13, 2025 · NOC 35014 · Abbreviated New Drug Submission (ANDS)
- NB-CITALOPRAMMarch 5, 2025 · NOC 34946 · Abbreviated New Drug Submission (ANDS)
- NB-PERINDOPRILFebruary 27, 2025 · NOC 34913 · Abbreviated New Drug Submission (ANDS)
- NB-ATORVASTATINFebruary 20, 2025 · NOC 34873 · Abbreviated New Drug Submission (ANDS)
- NB-ROSUVASTATINFebruary 14, 2025 · NOC 34841 · Abbreviated New Drug Submission (ANDS)
- NB-RISPERIDONEFebruary 7, 2025 · NOC 34802 · Abbreviated New Drug Submission (ANDS)
- NB-RIVAROXABANJanuary 31, 2025 · NOC 34784 · Abbreviated New Drug Submission (ANDS)
- NB-PREGABALINJanuary 22, 2025 · NOC 34716 · Abbreviated New Drug Submission (ANDS)
- NB-APIXABANNovember 28, 2024 · NOC 34472 · Abbreviated New Drug Submission (ANDS)